<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28976989</article-id><article-id pub-id-type="pmc">5627906</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0185449</article-id><article-id pub-id-type="publisher-id">PONE-D-17-17338</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical compounds</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>Vitamin D</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic chemistry</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>Vitamin D</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Nitric Oxide</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Nitric Oxide</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Basic Amino Acids</subject><subj-group><subject>Arginine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Basic Amino Acids</subject><subj-group><subject>Arginine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Basic Amino Acids</subject><subj-group><subject>Arginine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Cross-Sectional Studies</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Vitamin D and methylarginines in chronic kidney disease (CKD)</article-title><alt-title alt-title-type="running-head">Vitamin D and methylarginines in CKD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Torino</surname><given-names>Claudia</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Pizzini</surname><given-names>Patrizia</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Cutrupi</surname><given-names>Sebastiano</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Tripepi</surname><given-names>Rocco</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Tripepi</surname><given-names>Giovanni</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Mallamaci</surname><given-names>Francesca</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6616-1996</contrib-id><name><surname>Zoccali</surname><given-names>Carmine</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="corresp" rid="cor001">*</xref><xref ref-type="aff" rid="aff001"/></contrib></contrib-group><aff id="aff001"><addr-line>CNR-IFC, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension &#x00026; Nephrology and Renal Transplantation Unit, Reggio Calabria, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cozzolino</surname><given-names>Mario</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Milan, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>CZ received honoraria for lectures from AbbVie, Amgen, Genzyme, Roche, Shire. FM received honoraria for lectures by Amgen and Shire and GT by AbbVie. The other authors report no conflict of interest.This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>carmine.zoccali@tin.it</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>10</issue><elocation-id>e0185449</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Torino et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Torino et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0185449.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.</p></sec><sec id="sec002"><title>Methods</title><p>In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 &#x003bc;g/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.</p></sec><sec id="sec003"><title>Results</title><p>Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 &#x003bc;Mol/L (95%CI: 0.70&#x02013;0.81), 12 week 0.72 &#x003bc;Mol/L (95%CI: 0.66&#x02013;0.78); Placebo: baseline 0.75 &#x003bc;Mol/L (95%CI: 0.70&#x02013;0.90) 12 weeks 0.70 &#x003bc;Mol/L (95%CI: 0.66&#x02013;0.74)] and SDMA [Paricalcitol: baseline 0.91 &#x003bc;Mol/L (95%CI: 0.82&#x02013;1.00), 12 week 0.94 &#x003bc;Mol/L (95%CI: 0.82&#x02013;0.1.06); Placebo: baseline 0.91 &#x003bc;Mol/L (95%CI: 0.82&#x02013;1.06) 12 weeks 0.99 &#x003bc;Mol/L (95%CI: 0.88&#x02013;1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.</p></sec><sec id="sec004"><title>Conclusions</title><p>Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3&#x02013;4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006483</institution-id><institution>AbbVie</institution></institution-wrap></funding-source></award-group><funding-statement>Our institution received funding by AbbVie for the PENNY study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="10"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data are available from doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.997306">10.5281/zenodo.997306</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data are available from doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.997306">10.5281/zenodo.997306</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Asymmetric dimethyl arginine (ADMA) and its symmetric enantiomer, symmetric dimethyl arginine (SDMA), are endogenous inhibitors of the enzyme that regulates the synthesis of nitric oxide (NO), NO synthase. ADMA and SDMA have been associated with atherosclerosis and with cardiovascular[<xref rid="pone.0185449.ref001" ref-type="bibr">1</xref>] and renal diseases[<xref rid="pone.0185449.ref002" ref-type="bibr">2</xref>]. ADMA has been implicated in the pathogenesis of various conditions including Alzheimer's dementia[<xref rid="pone.0185449.ref003" ref-type="bibr">3</xref>], insulin resistance [<xref rid="pone.0185449.ref004" ref-type="bibr">4</xref>], thyroid dysfunction[<xref rid="pone.0185449.ref005" ref-type="bibr">5</xref>], fertility [<xref rid="pone.0185449.ref006" ref-type="bibr">6</xref>] and erectile dysfunction[<xref rid="pone.0185449.ref007" ref-type="bibr">7</xref>]. These compounds accumulate in chronic kidney disease and are considered as full-fledged uremic toxins[<xref rid="pone.0185449.ref008" ref-type="bibr">8</xref>].</p><p>NO synthase is expressed in bone cells and in these cells NO functions as a transducer of mechanosensitive signals [<xref rid="pone.0185449.ref009" ref-type="bibr">9</xref>]. In the rat plasma ADMA is inversely related with bone mass [<xref rid="pone.0185449.ref010" ref-type="bibr">10</xref>] and in mice this methylarginine inhibits osteoblastic differentiation, an effect which is reversed by the administration of the NO precursor L-arginine[<xref rid="pone.0185449.ref011" ref-type="bibr">11</xref>]. Sparse observations in various conditions support the hypothesis that ADMA may be a relevant player in mineral bone disorders. Indeed, in type 2 diabetics the plasma concentration of this biomarker associates with serum PTH independently of other factors [<xref rid="pone.0185449.ref012" ref-type="bibr">12</xref>]. In the general population [<xref rid="pone.0185449.ref013" ref-type="bibr">13</xref>] and in the elderly population [<xref rid="pone.0185449.ref014" ref-type="bibr">14</xref>] low 25-hydroxyvitamin D3 (25-OH Vit D) correlates inversely with ADMA and seasonal fluctuations in 25-OH Vit D associate with reciprocal ADMA fluctuations [<xref rid="pone.0185449.ref013" ref-type="bibr">13</xref>]. An inverse relationship between ADMA and 25-OH Vit D has been described in stage G5D CKD patients [<xref rid="pone.0185449.ref015" ref-type="bibr">15</xref>]. The possibility that the link between vitamin D in CKD and ADMA is causal in nature is suggested by the fact that in cross sectional analyses the plasma concentration of ADMA is halved in patients on treatment with vitamin D receptor antagonists like paricalcitol as compared to patients not receiving such a treatment [<xref rid="pone.0185449.ref016" ref-type="bibr">16</xref>]. Of note, in the same study an apparent dose-response relationship between the dose of paricalcitol and the degree of ADMA suppression was described [<xref rid="pone.0185449.ref016" ref-type="bibr">16</xref>]. However precious for hypothesis generation, cross sectional analyses are inherently inadequate to assess causation[<xref rid="pone.0185449.ref017" ref-type="bibr">17</xref>] and therefore it remains unresolved whether activation of the vitamin D receptor may suppress ADMA. We have now tested the nature of the link between vitamin D and methylarginines within the frame of a recent double-blind, randomized, controlled clinical trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY) study (clinicaltrials.gov identifier: NCT01680198). In this trial we systematically measured ADMA and SDMA in each study participant at all time-points of the study with no missing sample and herein report the results of analyses related to these methylarginines.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><p>The study protocol was approved by the ethics committee of our Institution, Comitato Etico Sezione Sud&#x02014;Regione Calabria, and a written informed consent was obtained from each participant.</p><sec id="sec007"><title>Patients</title><p>The protocol of the PENNY trial and the CONSORT flow diagram of this trial are reported into detail in the source study[<xref rid="pone.0185449.ref018" ref-type="bibr">18</xref>]. Briefly, PENNY is a double-blind, randomized, parallel group trial (ClinicalTrials.gov identifier, NCT01680198) enrolling 88 patients with CKD stage 3 to 4, age ranging between 18 and 80 years, parathormone &#x02265; 65 pg/ml, serum total Ca between 2.2 and 2.5 mmol/L and phosphate levels between 2.9 mg/dL and 4,5 mg/dL, not in treatment with vitamin D compounds or anti-epileptic drugs, without neoplasia or symptomatic cardiovascular disease or liver disease. Patients who met the inclusion criteria were randomized (1:1) to receive 2 &#x003bc;g paricalcitol once daily or matching placebo for 12 weeks after a 2-week run-in. The dose of paricalcitol was adjusted on the basis of serum parathormone and Ca and the maximum dose allowed was 2 &#x003bc;g daily. No vitamin D compounds were allowed during the trial. Demographic, clinical and biochemical data of the two study arms are listed in <xref ref-type="table" rid="pone.0185449.t001">Table 1</xref>.</p><table-wrap id="pone.0185449.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185449.t001</object-id><label>Table 1</label><caption><title>Demographic, clinical and biochemical characteristics of the two study arms at baseline.</title></caption><alternatives><graphic id="pone.0185449.t001g" xlink:href="pone.0185449.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Active group<break/>(n = 44)</th><th align="center" rowspan="1" colspan="1">Placebo group<break/>(n = 44)</th><th align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">63&#x000b1;11</td><td align="center" rowspan="1" colspan="1">62&#x000b1;12</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex (%)</td><td align="center" rowspan="1" colspan="1">59%</td><td align="center" rowspan="1" colspan="1">70%</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smokers (%)</td><td align="center" rowspan="1" colspan="1">12%</td><td align="center" rowspan="1" colspan="1">19%</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Past smokers (%)</td><td align="center" rowspan="1" colspan="1">45%</td><td align="center" rowspan="1" colspan="1">41%</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" rowspan="1" colspan="1">34%</td><td align="center" rowspan="1" colspan="1">36%</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29&#x000b1;5</td><td align="center" rowspan="1" colspan="1">29&#x000b1;5</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic/Diastolic BP (mmHg)</td><td align="center" rowspan="1" colspan="1">123&#x000b1;16/73&#x000b1;9</td><td align="center" rowspan="1" colspan="1">129&#x000b1;21/73&#x000b1;11</td><td align="center" rowspan="1" colspan="1">0.16/0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats/min)</td><td align="center" rowspan="1" colspan="1">67&#x000b1;8</td><td align="center" rowspan="1" colspan="1">68&#x000b1;10</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">164&#x000b1;41</td><td align="center" rowspan="1" colspan="1">162&#x000b1;43</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL Cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">47&#x000b1;11</td><td align="center" rowspan="1" colspan="1">50&#x000b1;13</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL Cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">88&#x000b1;34</td><td align="center" rowspan="1" colspan="1">88&#x000b1;36</td><td align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR<sub>Cyst</sub> (ml/min/1.73m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">34&#x000b1;12</td><td align="center" rowspan="1" colspan="1">29&#x000b1;13</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">12&#x000b1;2</td><td align="center" rowspan="1" colspan="1">12&#x000b1;2</td><td align="center" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.25&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">2.21&#x000b1;0.10</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Phosphate (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.20&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">1.23&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Parathormone (pg/mL)</td><td align="center" rowspan="1" colspan="1">102 (81&#x02013;146)</td><td align="center" rowspan="1" colspan="1">102 (85&#x02013;154)</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">FGF-23 (pg/mL)</td><td align="center" rowspan="1" colspan="1">64.7 (52.7&#x02013;81.2)</td><td align="center" rowspan="1" colspan="1">78.0 (53.7&#x02013;103.1)</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">1,25-OH vitamin D (pmol/L)</td><td align="center" rowspan="1" colspan="1">101.4&#x000b1;41.6</td><td align="center" rowspan="1" colspan="1">93.6&#x000b1;41.8</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">25-OH vitamin D (nmol/L)</td><td align="center" rowspan="1" colspan="1">33&#x000b1;16</td><td align="center" rowspan="1" colspan="1">38&#x000b1;16</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">C reactive protein (mg/L)</td><td align="center" rowspan="1" colspan="1">1.18 (0.68&#x02013;3.02)</td><td align="center" rowspan="1" colspan="1">2.49 (0.99&#x02013;3.74)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">ADMA (&#x003bc;Mol/L)</td><td align="center" rowspan="1" colspan="1">0.75&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">0.75&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">SDMA (&#x003bc;Mol/L)</td><td align="center" rowspan="1" colspan="1">0.91&#x000b1;0.30</td><td align="center" rowspan="1" colspan="1">0.91&#x000b1;0.30</td><td align="center" rowspan="1" colspan="1">0.92</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Data are expressed as mean&#x000b1; SD, median and inter-quartile range or as percent frequency as appropriate.</p></fn><fn id="t001fn002"><p>Abbreviations: BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; GFR, glomerular filtration rate; FGF-23, fibroblast growth factor-23.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Laboratory measurements</title><p>Serum calcium, phosphate, glucose, lipids were measured in the routine clinical pathology laboratory at our Institution. Serum creatinine was measured by the Roche enzymatic, IDMS calibrated method and serum cystatin C by the Siemens Dade Behring kit and the GFR was calculated by the CKD-Epi creatinine-cystatin formula [<xref rid="pone.0185449.ref019" ref-type="bibr">19</xref>]. Plasma parathormone was measured by immunoradiometric assay (DiaSorin Stillwater, MN, USA), 25 OH Vit D and 1,25 (OH)<sub>2</sub> Vit D by radioimmunoassay (Immunodiagnostic Systems, Boldon, UK). Plasma ADMA [<xref rid="pone.0185449.ref020" ref-type="bibr">20</xref>] and SDMA [<xref rid="pone.0185449.ref021" ref-type="bibr">21</xref>] were measured by validated ELISA methods by using commercially available kits by DLD Gesellschaft f&#x000fc;r Diagnostika, Hamburg, Germany. Normal ranges of plasma ADMA and SDMA determined by this method are 0.40&#x02013;0.75 and 0.30&#x02013;0.70 mMol/L, respectively. Plasma samples were kept frozen at -80&#x000b0; degrees, without freeze-thaw cycles, until analysis and ADMA and SDMA measurements were measured in a single assay.</p></sec><sec id="sec009"><title>Statistical analysis</title><p>Data are reported as mean &#x000b1; standard deviation (normally distributed data), median and inter-quartile range (non-normally distributed data) or as percent frequency, and comparison between groups were made by independent T-Test, Mann-Whitney Test, or Chi Square test. Correlates of methylarginines and of paricalcitol-induced changes in methylarginines were analyzed by using the Pearson&#x02019;s correlation coefficient (on log<sub>10</sub> transformed data, when appropriate). All comparison were appropriately adjusted for multiple testing. The effect of paricalcitol on plasma ADMA and SDMA was analyzed by comparing the changes in these indices in paricalcitol-treated and untreated patients by using the T-Test for independent observations. The potential effect modification by demographic (age and gender) and bone mineral disorder biomarkers at baseline [calcium, phosphate, 25-OH Vit D, 1,25-(OH)<sub>2</sub> Vit D, PTH and FGF23] on the relationship between allocation arm and plasma methylarginines was investigated by standard interaction analyses by creating appropriate multiplicative terms [<xref rid="pone.0185449.ref022" ref-type="bibr">22</xref>]. All P values in this analyses were appropriately adjusted for multiple comparisons (Bonferroni correction). Differences in risk factors at baseline not controlled by randomization and due to chance were accounted by using multiple regression. Data analysis was performed by SPSS for Windows (version 20.0, Chicago, Illinois, USA).</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><p>At baseline, patients randomized to paricalcitol and placebo did not differ for demographic, clinical and biochemical characteristics, except for the eGFR which tended to be higher in patients receiving paricalcitol (P = 0.06) (<xref ref-type="table" rid="pone.0185449.t001">Table 1</xref>). Vitamin D insufficiency (&#x0003e;25 nmol/L &#x0003c;75 nmol/L) or deficiency (&#x0003c;25 nmol/L) was present in the vast majority (95%) of patients with no between-arms difference (42 patients in each group). The proportion of patients with elevated ADMA and SDMA (i.e. presenting levels above the upper limit of the normal range of each indicator) was 39% for ADMA and 73% for SDMA. Alongside with strictly comparable plasma levels of bone disorder biomarkers, the average values of these biomarkers at baseline were very similar in the two study arms (<xref ref-type="table" rid="pone.0185449.t001">Table 1</xref>). As reported in detail in the source study[<xref rid="pone.0185449.ref018" ref-type="bibr">18</xref>] and in <xref ref-type="table" rid="pone.0185449.t002">Table 2</xref>, drug treatments, including ACE inhibitors, sartans, hypoglicemizing agents, statins and proton pump inhibitors, were similar between the two groups except for calcium carbonate, this latter compound being more frequently administered in patients on placebo (22.7%) than in those in the paricalcitol arm (0%) (P = .003).</p><table-wrap id="pone.0185449.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185449.t002</object-id><label>Table 2</label><caption><title>Drug treatments in the two study arms.</title></caption><alternatives><graphic id="pone.0185449.t002g" xlink:href="pone.0185449.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Active group<break/>(n = 44)</th><th align="center" rowspan="1" colspan="1">Placebo group<break/>(n = 44)</th><th align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACE inhibitors (%)</td><td align="center" rowspan="1" colspan="1">47.7%</td><td align="center" rowspan="1" colspan="1">47.7%</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Angiotensin Receptor Blockers (%)</td><td align="center" rowspan="1" colspan="1">59.1%</td><td align="center" rowspan="1" colspan="1">47.7%</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretics (%)</td><td align="center" rowspan="1" colspan="1">34.1%</td><td align="center" rowspan="1" colspan="1">47.7%</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Alpha and Beta Blockers (%)</td><td align="center" rowspan="1" colspan="1">36.4%</td><td align="center" rowspan="1" colspan="1">38.6%</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium Antagonists (%)</td><td align="center" rowspan="1" colspan="1">40.9%</td><td align="center" rowspan="1" colspan="1">52.3%</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins (%)</td><td align="center" rowspan="1" colspan="1">45.5%</td><td align="center" rowspan="1" colspan="1">52.5%</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Omega 3 polyunsaturated fatty acids (%)</td><td align="center" rowspan="1" colspan="1">27.3%</td><td align="center" rowspan="1" colspan="1">11.4%</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypoglycemizing agents (%)</td><td align="center" rowspan="1" colspan="1">6.8%</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin (%)</td><td align="center" rowspan="1" colspan="1">13.6%</td><td align="center" rowspan="1" colspan="1">15.9%</td><td align="center" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiplatelet agents (%)</td><td align="center" rowspan="1" colspan="1">50.0%</td><td align="center" rowspan="1" colspan="1">54.5%</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitrates (%)</td><td align="center" rowspan="1" colspan="1">9.1%</td><td align="center" rowspan="1" colspan="1">4.5%</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythropoietin stimulating agents (%)</td><td align="center" rowspan="1" colspan="1">2.3%</td><td align="center" rowspan="1" colspan="1">2.0%</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Iron (%)</td><td align="center" rowspan="1" colspan="1">11.4%</td><td align="center" rowspan="1" colspan="1">13.6%</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium carbonate (%)</td><td align="center" rowspan="1" colspan="1">0.0%</td><td align="center" rowspan="1" colspan="1">22.7%</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Proton pump inhibitors (%)</td><td align="center" rowspan="1" colspan="1">63.6%</td><td align="center" rowspan="1" colspan="1">50.0%</td><td align="center" rowspan="1" colspan="1">0.20</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Data are expressed as percent frequency and compared by the Chi Square Test (with the continuity correction when appropriate).</p></fn></table-wrap-foot></table-wrap><sec id="sec011"><title>Functional correlates of ADMA and SDMA in CKD patients</title><p>In the cross sectional analysis made at baseline, ADMA and SDMA were inter-related (r = 0.272, P&#x0003c;0.01). ADMA and SDMA correlated inversely with the GFR-Cys-creat and SDMA exhibited a stronger link with this parameter (r = -0.566, P&#x0003c;0.001) than ADMA (r = -0.376, P&#x0003c;0.001). Furthermore, SDMA but not ADMA was inversely related with age (r = -0.275, P = 0.009), serum phosphorus (r = 0.293, P = 0.006), PTH (r = 0.306, P = 0.004), 1.25-(OH)<sub>2</sub> Vit D (r = -0.243, P = 0.0023) as well as with FGF23 (r = 0.226, P = 0.034). However, in analyses adjusting for age and the GFR-cys-creat, two relevant confounders for the link between SDMA and bone mineral disorder biomarkers, all these associations failed to maintain an independent association with SDMA [Phosphorus-SDMA &#x003b2; = 0.001, P = 0.99; PTH-SDMA &#x003b2; = 0.178, P = 0.06; 1,25-(OH)<sub>2</sub> Vit D-SDMA &#x003b2; = -0.055, P = 0.54; FGF23-SDMA &#x003b2; = 0.135, P = 0.11].</p></sec><sec id="sec012"><title>Effects of paricalcitol on plasma ADMA and SDMA</title><p>Paricalcitol produced a modest rise in serum calcium and phosphate, the expected suppression in PTH and 1,25-OH vitamin D, a marked rise in FGF23 and no change in 25-OH vit D (see <xref ref-type="fig" rid="pone.0185449.g001">Fig 1</xref> and Ref [<xref rid="pone.0185449.ref018" ref-type="bibr">18</xref>]). However, vitamin D receptor activation by this drug largely failed to modify ADMA and SDMA that remained unchanged both during paricalcitol and placebo and after stopping these treatments (<xref ref-type="fig" rid="pone.0185449.g001">Fig 1</xref>). These results did not change after adjustment for the eGFR (P = 0.97 and P = 0.43) or for calcium carbonate treatment, i.e. the two variables that were different at baseline in two study arms. No effect modification by age, gender, baseline 25-OH vitamin D, 1,25-OH vitamin D, calcium, phosphate, PTH and FGF23 on ADMA, SDMA was noted.</p><fig id="pone.0185449.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185449.g001</object-id><label>Fig 1</label><caption><title>Changes in bone mineral disorder biomarkers, ADMA and SDMA according to the treatment group (paricalcitol/placebo).</title><p>The bars correspond to 95%CI.</p></caption><graphic xlink:href="pone.0185449.g001"/></fig></sec></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>In this trial vitamin D receptor activation by paricalcitol produced the expected effects on calcium, phosphate, PTH, FGF23 and 1,25-(OH)<sub>2</sub> vitamin D but left completely unmodified the plasma concentration of ADMA and SDMA.</p><p>Even though there is still no trial based on clinical end-points targeting ADMA and SDMA, these methylarginines are regarded as important risk factors for death [<xref rid="pone.0185449.ref023" ref-type="bibr">23</xref>] [<xref rid="pone.0185449.ref024" ref-type="bibr">24</xref>], cardiovascular disease [<xref rid="pone.0185449.ref025" ref-type="bibr">25</xref>] and progression to kidney failure[<xref rid="pone.0185449.ref026" ref-type="bibr">26</xref>] [<xref rid="pone.0185449.ref027" ref-type="bibr">27</xref>]. Various drugs can modify the plasma concentration of ADMA. ACE-inhibitors like perindopril[<xref rid="pone.0185449.ref028" ref-type="bibr">28</xref>] or enalapril[<xref rid="pone.0185449.ref029" ref-type="bibr">29</xref>] or zofenopril[<xref rid="pone.0185449.ref030" ref-type="bibr">30</xref>] as well as the angiotensin II receptor blocker eprosartan[<xref rid="pone.0185449.ref029" ref-type="bibr">29</xref>] produce a modest lowering in the plasma concentration of ADMA but it is unclear whether this effect is related to their anti-hypertensive action or to interference with ADMA metabolism. Metformin reduces ADMA in diabetics [<xref rid="pone.0185449.ref031" ref-type="bibr">31</xref>] and the peroxisome proliferator activated receptor agonist rosiglitazone lowers ADMA in patients with insulin resistance[<xref rid="pone.0185449.ref032" ref-type="bibr">32</xref>]. Estrogens in postmenopausal woman have a consistent but minor ADMA lowering effect [<xref rid="pone.0185449.ref033" ref-type="bibr">33</xref>]. Overall, these drugs have modest effects on ADMA and given the interference of ADMA and SDMA with a pathway (NO synthesis) of critical relevance for cardiovascular[<xref rid="pone.0185449.ref001" ref-type="bibr">1</xref>] and renal disease[<xref rid="pone.0185449.ref002" ref-type="bibr">2</xref>], the search of new drugs producing a biologically relevant decrease of these methylarginines is an important undertaking with potential implications for clinical practice. Vascular dysfunction appears to be tightly associated with high ADMA levels in CKD patients[<xref rid="pone.0185449.ref034" ref-type="bibr">34</xref>]. Paricalcitol coherently improves vascular dysfunction by increasing the NO-dependent forearm flow mediated vasodilatation in response to ischemia[<xref rid="pone.0185449.ref018" ref-type="bibr">18</xref>] [<xref rid="pone.0185449.ref035" ref-type="bibr">35</xref>] in these patients. Also because the previously mentioned links of ADMA with a fundamental biomarker of mineral bone disorders like PTH [<xref rid="pone.0185449.ref012" ref-type="bibr">12</xref>] and the inverse seasonal fluctuations of ADMA and 25-OH Vit D[<xref rid="pone.0185449.ref036" ref-type="bibr">36</xref>], vitamin D receptor activation appears to be an interesting, novel pathway to explore to mitigate ADMA accumulation in CKD. Descriptive, cross-sectional studies would support the possibility of a biologically important effect of vitamin D on ADMA levels in CKD because the plasma concentration of this compound is more than halved in patients on chronic paricalcitol treatment as compared to those that do not take this drug[<xref rid="pone.0185449.ref016" ref-type="bibr">16</xref>]. Furthermore, categorical analyses in the same study show that among patients in the fourth ADMA quartile the proportion of patients not on paricalcitol is 3.5 times lower than that of patients in the first ADMA quartile[<xref rid="pone.0185449.ref016" ref-type="bibr">16</xref>].</p><p>The PENNY study contemplated the creation of a biological databank for exploring scientific hypotheses related with vitamin D activation in CKD and serum samples were available for all patients enrolled into this trial. Therefore this double blind randomized trial represents an ideal basis for experimentally testing whether this drug can modify plasma methylarginines levels.</p><p>Like in a previous study applying an inactive form of vitamin D [<xref rid="pone.0185449.ref037" ref-type="bibr">37</xref>], in the present study paricalcitol substantially reduced circulating and perhaps intracellular 1,25 &#x02013;OH vitamin D levels thereby limiting the VDR exposure to the main endogenous agonist of this receptor. Our data show that a powerful synthetic VDR agonist given at adequate pharmacological doses sufficient to suppress PTH (a major effect of VDR stimulation) largely fails to modify ADMA levels. Overall it seems unlikely that low intracellular 1,25-vitamin D might justify the complete lack of the ADMA-response to VDR stimulation.</p><p>In contrast with the cross-sectional analysis by Oliva-Damaso et al.,[<xref rid="pone.0185449.ref016" ref-type="bibr">16</xref>] paricalcitol had a robustly null effect on the plasma concentration of ADMA and SDMA and extensive interaction analyses showed no modification of the effect of paricalcitol on these methylargines in relationship with demographic factors (age, gender) and the main biomarkers of the mineral bone disorder in CKD including calcium, phosphate, 25-OH vitamin D, 1,25-(OH)<sub>2</sub> vitamin D, PTH and FGF23. Confounding by indication is a well-known bias of associations detected in cross-sectional studies[<xref rid="pone.0185449.ref038" ref-type="bibr">38</xref>]. The possibility that paracalcitol was preferentially prescribed to patients at lower risk for cardiovascular disease, i.e. to patients who typically exhibit lower ADMA levels, might explain the much lower levels in the plasma concentration of this compound in patients treated with this drug as compared to patients not receiving this treatment. Even though Oliva-Damaso et al., made meaningful adjustments to minimize confounding by indication, this bias is difficult to remove in observational studies and therefore the possibility of residual confounding in the same study appears much likely. A survival advantage by paricalcitol was noted in observational studies analyzed by state of art statistical techniques including propensity matching [<xref rid="pone.0185449.ref039" ref-type="bibr">39</xref>] and marginal structural models [<xref rid="pone.0185449.ref040" ref-type="bibr">40</xref>] while no signal for a reduced death risk or an attenuation in the progression of left ventricular hypertrophy was registered in a subsequent double blind randomized trial testing the effects of paricalcitol in predialysis CKD patients[<xref rid="pone.0185449.ref041" ref-type="bibr">41</xref>]. However intriguing, the hypothesis that an ADMA lowering effect by paricalcitol may mediate the apparent survival advantage of patients treated by this drug is negated by the robustly negative findings in the PENNY trial.</p><p>In conclusion, analyses performed within the frame of a double blind randomized trial, do not confirm cross-sectional analyses showing a favorable effect of this drug on circulating levels of the two main methylargines, ADMA and SDMA. The purported favorable effect of paracalcitol on cardiovascular outcomes does not appear justified by an ADMA and/or SDMA lowering effect of this vitamin D receptor activator.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0185449.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name>, <name><surname>Maas</surname><given-names>R</given-names></name>, <name><surname>Schulze</surname><given-names>F</given-names></name>, <name><surname>Schwedhelm</surname><given-names>E</given-names></name>. <article-title>Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality&#x02014;An update on patient populations with a wide range of cardiovascular risk</article-title>. <source>Pharmacol Res</source>. <year>2009</year>;<volume>60</volume>: <fpage>481</fpage>&#x02013;<lpage>487</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.phrs.2009.07.001">10.1016/j.phrs.2009.07.001</ext-link></comment>
<pub-id pub-id-type="pmid">19596069</pub-id></mixed-citation></ref><ref id="pone.0185449.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Schwedhelm</surname><given-names>E</given-names></name>, <name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name>. <article-title>The role of asymmetric and symmetric dimethylarginines in renal disease</article-title>. <source>Nat Rev Nephrol</source>. Nature Publishing Group; <year>2011</year>;<volume>7</volume>: <fpage>275</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneph.2011.31">10.1038/nrneph.2011.31</ext-link></comment>
<pub-id pub-id-type="pmid">21445101</pub-id></mixed-citation></ref><ref id="pone.0185449.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Selley</surname><given-names>ML</given-names></name>. <article-title>Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer&#x02019;s disease</article-title>. <source>Neurobiol Aging</source>. <year>2003</year>;<volume>24</volume>: <fpage>903</fpage>&#x02013;<lpage>907</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0197-4580(03)00007-1">10.1016/S0197-4580(03)00007-1</ext-link></comment>
<pub-id pub-id-type="pmid">12928048</pub-id></mixed-citation></ref><ref id="pone.0185449.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>St&#x000fc;hlinger</surname><given-names>MC</given-names></name>, <name><surname>Abbasi</surname><given-names>F</given-names></name>, <name><surname>Chu</surname><given-names>JW</given-names></name>, <name><surname>Lamendola</surname><given-names>C</given-names></name>, <name><surname>McLaughlin</surname><given-names>TL</given-names></name>, <name><surname>Cooke</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>: <fpage>1420</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">11903029</pub-id></mixed-citation></ref><ref id="pone.0185449.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hermenegildo</surname><given-names>C</given-names></name>, <name><surname>Medina</surname><given-names>P</given-names></name>, <name><surname>Peir&#x000f3;</surname><given-names>M</given-names></name>, <name><surname>Segarra</surname><given-names>G</given-names></name>, <name><surname>Vila</surname><given-names>JM</given-names></name>, <name><surname>Ortega</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>: <fpage>5636</fpage>&#x02013;<lpage>5640</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2002-020905">10.1210/jc.2002-020905</ext-link></comment>
<pub-id pub-id-type="pmid">12466365</pub-id></mixed-citation></ref><ref id="pone.0185449.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Holden</surname><given-names>DP</given-names></name>, <name><surname>Cartwright</surname><given-names>JE</given-names></name>, <name><surname>Nussey</surname><given-names>SS</given-names></name>, <name><surname>Whitley</surname><given-names>GSJ</given-names></name>. <article-title>Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>: <fpage>1575</fpage>&#x02013;<lpage>1580</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.CIR.0000091083.61609.DF">10.1161/01.CIR.0000091083.61609.DF</ext-link></comment>
<pub-id pub-id-type="pmid">12963642</pub-id></mixed-citation></ref><ref id="pone.0185449.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Maas</surname><given-names>R</given-names></name>, <name><surname>Schwedhelm</surname><given-names>E</given-names></name>, <name><surname>Albsmeier</surname><given-names>J</given-names></name>, <name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name>. <article-title>The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function</article-title>. <source>Vasc Med</source>. <year>2002</year>;<volume>7</volume>: <fpage>213</fpage>&#x02013;<lpage>225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1191/1358863x02vm429ra">10.1191/1358863x02vm429ra</ext-link></comment>
<pub-id pub-id-type="pmid">12553745</pub-id></mixed-citation></ref><ref id="pone.0185449.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Vanholder</surname><given-names>R</given-names></name>, <name><surname>Baurmeister</surname><given-names>U</given-names></name>, <name><surname>Brunet</surname><given-names>P</given-names></name>, <name><surname>Cohen</surname><given-names>G</given-names></name>, <name><surname>Glorieux</surname><given-names>G</given-names></name>, <name><surname>Jankowski</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>A bench to bedside view of uremic toxins</article-title>. <source>J Am Soc Nephrol</source>. <year>2008</year>;<volume>19</volume>: <fpage>863</fpage>&#x02013;<lpage>870</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2007121377">10.1681/ASN.2007121377</ext-link></comment>
<pub-id pub-id-type="pmid">18287557</pub-id></mixed-citation></ref><ref id="pone.0185449.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Mullender</surname><given-names>M</given-names></name>, <name><surname>El Haj</surname><given-names>AJ</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>van Duin</surname><given-names>MA</given-names></name>, <name><surname>Burger</surname><given-names>EH</given-names></name>, <name><surname>Klein-Nulend</surname><given-names>J</given-names></name>. <article-title>Mechanotransduction of bone cells in vitro: Mechanobiology of bone tissue</article-title>. <source>Medical and Biological Engineering and Computing</source>. <year>2004</year> pp. <fpage>14</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/BF02351006">10.1007/BF02351006</ext-link></comment>
<pub-id pub-id-type="pmid">14977218</pub-id></mixed-citation></ref><ref id="pone.0185449.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>R</given-names></name>, <name><surname>Hu</surname><given-names>C-P</given-names></name>, <name><surname>Wu</surname><given-names>X-P</given-names></name>, <name><surname>Liao</surname><given-names>E-Y</given-names></name>, <name><surname>Li</surname><given-names>Y-J</given-names></name>. <article-title>Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats</article-title>. <source>Comp Med</source>. <year>2002</year>;<volume>52</volume>: <fpage>224</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">12102566</pub-id></mixed-citation></ref><ref id="pone.0185449.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>ZS</given-names></name>, <name><surname>Quarles</surname><given-names>LD</given-names></name>, <name><surname>Chen</surname><given-names>QQ</given-names></name>, <name><surname>Yu</surname><given-names>YH</given-names></name>, <name><surname>Qu</surname><given-names>XP</given-names></name>, <name><surname>Jiang</surname><given-names>CH</given-names></name>, <etal>et al</etal>
<article-title>Effect of asymmetric dimethylarginine on osteoblastic differentiation</article-title>. <source>Kidney Int</source>. <year>2001</year>;<volume>60</volume>: <fpage>1699</fpage>&#x02013;<lpage>1704</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1523-1755.2001.00011.x">10.1046/j.1523-1755.2001.00011.x</ext-link></comment>
<pub-id pub-id-type="pmid">11703587</pub-id></mixed-citation></ref><ref id="pone.0185449.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Amarasekera</surname><given-names>AT</given-names></name>, <name><surname>Sverdlov</surname><given-names>AL</given-names></name>, <name><surname>Horowitz</surname><given-names>JD</given-names></name>, <name><surname>Ngo</surname><given-names>DT</given-names></name>. <article-title>Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients</article-title>. <source>Diabetes Metab</source>. <year>2016</year>;<volume>42</volume>: <fpage>378</fpage>&#x02013;<lpage>381</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.diabet.2016.05.002">10.1016/j.diabet.2016.05.002</ext-link></comment>
<pub-id pub-id-type="pmid">27286738</pub-id></mixed-citation></ref><ref id="pone.0185449.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ngo</surname><given-names>DT</given-names></name>, <name><surname>Sverdlov</surname><given-names>AL</given-names></name>, <name><surname>McNeil</surname><given-names>JJ</given-names></name>, <name><surname>Horowitz</surname><given-names>JD</given-names></name>. <article-title>Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?</article-title>
<source>Am J Med</source>. <year>2010</year>;<volume>123</volume>: <fpage>335</fpage>&#x02013;<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjmed.2009.09.024">10.1016/j.amjmed.2009.09.024</ext-link></comment>
<pub-id pub-id-type="pmid">20362753</pub-id></mixed-citation></ref><ref id="pone.0185449.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HR</given-names></name>, <name><surname>Lee</surname><given-names>SW</given-names></name>, <name><surname>Yeom</surname><given-names>H</given-names></name>, <name><surname>Jeon</surname><given-names>D-H</given-names></name>, <name><surname>Kim</surname><given-names>HC</given-names></name>, <name><surname>Youm</surname><given-names>Y</given-names></name>. <article-title>Association between vitamin D status and asymmetric dimethylarginine (ADMA) concentration in the Korean elderly population</article-title>. <source>Maturitas</source>. <year>2017</year>;<volume>102</volume>: <fpage>13</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.maturitas.2017.05.002">10.1016/j.maturitas.2017.05.002</ext-link></comment>
<pub-id pub-id-type="pmid">28610677</pub-id></mixed-citation></ref><ref id="pone.0185449.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Bednarek-Skublewska</surname><given-names>A</given-names></name>, <name><surname>Smole&#x00144;</surname><given-names>A</given-names></name>, <name><surname>Jaroszy&#x00144;ski</surname><given-names>A</given-names></name>, <name><surname>Za&#x00142;uska</surname><given-names>W</given-names></name>, <name><surname>Ksi&#x00061;&#x00327;zek</surname><given-names>A</given-names></name>. <article-title>Effects of vitamin D3 on selected biochemical parameters of nutritional status, inflammation, and cardiovascular disease in patients undergoing long-term hemodialysis</article-title>. <source>Pol Arch Med Wewn</source>. <year>2010</year>;<volume>120</volume>: <fpage>167</fpage>&#x02013;<lpage>174</lpage>. <pub-id pub-id-type="pmid">20502401</pub-id></mixed-citation></ref><ref id="pone.0185449.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Oliva-Damaso</surname><given-names>E</given-names></name>, <name><surname>Oliva-Damaso</surname><given-names>N</given-names></name>, <name><surname>Rodriguez-Esparragon</surname><given-names>F</given-names></name>, <name><surname>Payan</surname><given-names>J</given-names></name>, <name><surname>Mara&#x000f1;es</surname><given-names>A</given-names></name>, <name><surname>Parodis</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol</article-title>. <source>Kidney Int Reports</source>. <year>2017</year>; <fpage>165</fpage>&#x02013;<lpage>171</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ekir.2016.10.002">10.1016/j.ekir.2016.10.002</ext-link></comment></mixed-citation></ref><ref id="pone.0185449.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>D&#x02019;Arrigo</surname><given-names>G</given-names></name>, <name><surname>Jager</surname><given-names>KJ</given-names></name>, <name><surname>Stel</surname><given-names>VS</given-names></name>, <name><surname>Dekker</surname><given-names>FW</given-names></name>, <name><surname>Zoccali</surname><given-names>C</given-names></name>. <article-title>Do we still need cross-sectional studies in Nephrology? Yes we do!</article-title>
<source>Nephrol Dial Transplant</source>. <year>2017</year>;<volume>32</volume>: <fpage>gfw439</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ndt/gfw439">10.1093/ndt/gfw439</ext-link></comment>
<pub-id pub-id-type="pmid">28088771</pub-id></mixed-citation></ref><ref id="pone.0185449.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Zoccali</surname><given-names>C</given-names></name>, <name><surname>Curatola</surname><given-names>G</given-names></name>, <name><surname>Panuccio</surname><given-names>V</given-names></name>, <name><surname>Tripepi</surname><given-names>R</given-names></name>, <name><surname>Pizzini</surname><given-names>P</given-names></name>, <name><surname>Versace</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial</article-title>. <source>Hypertension</source>. <year>2014</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/HYPERTENSIONAHA.114.03748">10.1161/HYPERTENSIONAHA.114.03748</ext-link></comment>
<pub-id pub-id-type="pmid">25259743</pub-id></mixed-citation></ref><ref id="pone.0185449.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Bosch</surname><given-names>JP</given-names></name>, <name><surname>Lewis</surname><given-names>JB</given-names></name>, <name><surname>Greene</surname><given-names>T</given-names></name>, <name><surname>Rogers</surname><given-names>N</given-names></name>, <name><surname>Roth</surname><given-names>D</given-names></name>. <article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>130</volume>: <fpage>461</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="pone.0185449.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Schulze</surname><given-names>F</given-names></name>, <name><surname>Wesemann</surname><given-names>R</given-names></name>, <name><surname>Schwedhelm</surname><given-names>E</given-names></name>, <name><surname>Sydow</surname><given-names>K</given-names></name>, <name><surname>Albsmeier</surname><given-names>J</given-names></name>, <name><surname>Cooke</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay</article-title>. <source>Clin Chem Lab Med</source>. <year>2004</year>;<volume>42</volume>: <fpage>1377</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1515/CCLM.2004.257">10.1515/CCLM.2004.257</ext-link></comment>
<pub-id pub-id-type="pmid">15576299</pub-id></mixed-citation></ref><ref id="pone.0185449.ref021"><label>21</label><mixed-citation publication-type="other">DLD-diagnostica. SDMA-Elisa [Internet].</mixed-citation></ref><ref id="pone.0185449.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>de Mutsert</surname><given-names>R</given-names></name>, <name><surname>Jager</surname><given-names>KJ</given-names></name>, <name><surname>Zoccali</surname><given-names>C</given-names></name>, <name><surname>Dekker</surname><given-names>FW</given-names></name>. <article-title>The effect of joint exposures: examining the presence of interaction</article-title>. <source>Kidney Int</source>. <year>2009</year>;<volume>75</volume>: <fpage>677</fpage>&#x02013;<lpage>681</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ki.2008.645">10.1038/ki.2008.645</ext-link></comment>
<pub-id pub-id-type="pmid">19190674</pub-id></mixed-citation></ref><ref id="pone.0185449.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Zoccali</surname><given-names>C</given-names></name>, <name><surname>Bode-B&#x000f6;ger</surname><given-names>S</given-names></name>, <name><surname>Mallamaci</surname><given-names>F</given-names></name>, <name><surname>Benedetto</surname><given-names>F</given-names></name>, <name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>Malatino</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>358</volume>: <fpage>2113</fpage>&#x02013;<lpage>2117</lpage>. <pub-id pub-id-type="pmid">11784625</pub-id></mixed-citation></ref><ref id="pone.0185449.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Aucella</surname><given-names>F</given-names></name>, <name><surname>Maas</surname><given-names>R</given-names></name>, <name><surname>Vigilante</surname><given-names>M</given-names></name>, <name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>Schwedhelm</surname><given-names>E</given-names></name>, <name><surname>Margaglione</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study</article-title>. <source>Atherosclerosis</source>. Elsevier Ireland Ltd; <year>2009</year>;<volume>207</volume>: <fpage>541</fpage>&#x02013;<lpage>545</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.atherosclerosis.2009.05.011">10.1016/j.atherosclerosis.2009.05.011</ext-link></comment>
<pub-id pub-id-type="pmid">19501358</pub-id></mixed-citation></ref><ref id="pone.0185449.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Zoccali</surname><given-names>C</given-names></name>, <name><surname>Mallamaci</surname><given-names>F</given-names></name>, <name><surname>Maas</surname><given-names>R</given-names></name>, <name><surname>Benedetto</surname><given-names>F a</given-names></name>, <name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>Malatino</surname><given-names>LS</given-names></name>, <etal>et al</etal>
<article-title>Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients</article-title>. <source>Kidney Int</source>. <year>2002</year>;<volume>62</volume>: <fpage>339</fpage>&#x02013;<lpage>345</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1523-1755.2002.00437.x">10.1046/j.1523-1755.2002.00437.x</ext-link></comment>
<pub-id pub-id-type="pmid">12081596</pub-id></mixed-citation></ref><ref id="pone.0185449.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Fliser</surname><given-names>D</given-names></name>, <name><surname>Kronenberg</surname><given-names>F</given-names></name>, <name><surname>Kielstein</surname><given-names>JT</given-names></name>, <name><surname>Morath</surname><given-names>C</given-names></name>, <name><surname>Bode-B&#x000f6;ger</surname><given-names>SM</given-names></name>, <name><surname>Haller</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>: <fpage>2456</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2005020179">10.1681/ASN.2005020179</ext-link></comment>
<pub-id pub-id-type="pmid">15930091</pub-id></mixed-citation></ref><ref id="pone.0185449.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Ravani</surname><given-names>P</given-names></name>, <name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>Malberti</surname><given-names>F</given-names></name>, <name><surname>Testa</surname><given-names>S</given-names></name>, <name><surname>Mallamaci</surname><given-names>F</given-names></name>, <name><surname>Zoccali</surname><given-names>C</given-names></name>. <article-title>Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>: <fpage>2449</fpage>&#x02013;<lpage>2455</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1681/ASN.2005010076">10.1681/ASN.2005010076</ext-link></comment>
<pub-id pub-id-type="pmid">15944335</pub-id></mixed-citation></ref><ref id="pone.0185449.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Ito</surname><given-names>a</given-names></name>, <name><surname>Egashira</surname><given-names>K</given-names></name>, <name><surname>Narishige</surname><given-names>T</given-names></name>, <name><surname>Muramatsu</surname><given-names>K</given-names></name>, <name><surname>Takeshita</surname><given-names>a</given-names></name>. <article-title>Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension</article-title>. <source>Jpn Circ J</source>. <year>2001</year>;<volume>65</volume>: <fpage>775</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">11548874</pub-id></mixed-citation></ref><ref id="pone.0185449.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Delles</surname><given-names>C</given-names></name>, <name><surname>Jacobi</surname><given-names>J</given-names></name>, <name><surname>John</surname><given-names>S</given-names></name>, <name><surname>Fleischmann</surname><given-names>I</given-names></name>, <name><surname>Schmieder</surname><given-names>RE</given-names></name>. <article-title>Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension</article-title>. <source>Kidney Int</source>. <year>2002</year>;<volume>61</volume>: <fpage>1462</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1523-1755.2002.00260.x">10.1046/j.1523-1755.2002.00260.x</ext-link></comment>
<pub-id pub-id-type="pmid">11918753</pub-id></mixed-citation></ref><ref id="pone.0185449.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Napoli</surname><given-names>R</given-names></name>, <name><surname>Biondi</surname><given-names>B</given-names></name>, <name><surname>Guardasole</surname><given-names>V</given-names></name>, <name><surname>Matarazzo</surname><given-names>M</given-names></name>, <name><surname>Pardo</surname><given-names>F</given-names></name>, <name><surname>Angelini</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Impact of hyperthyroidism and its correction on vascular reactivity in humans</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>: <fpage>3076</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="pmid">11748103</pub-id></mixed-citation></ref><ref id="pone.0185449.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Asagami</surname><given-names>T</given-names></name>, <name><surname>Abbasi</surname><given-names>F</given-names></name>, <name><surname>Stuelinger</surname><given-names>M</given-names></name>, <name><surname>Lamendola</surname><given-names>C</given-names></name>, <name><surname>McLaughlin</surname><given-names>T</given-names></name>, <name><surname>Cooke</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes</article-title>. <source>Metabolism</source>. <year>2002</year>;<volume>51</volume>: <fpage>843</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">12077728</pub-id></mixed-citation></ref><ref id="pone.0185449.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Stuhlinger</surname><given-names>MC</given-names></name>, <name><surname>Abbasi</surname><given-names>F</given-names></name>, <name><surname>Chu</surname><given-names>JW</given-names></name>, <name><surname>Lamendola</surname><given-names>C</given-names></name>, <name><surname>McLaughlin</surname><given-names>TL</given-names></name>, <name><surname>Cooke</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor</article-title>. <source>J Am Med Assoc</source>. <year>2002</year>;<volume>287</volume>: <fpage>1420</fpage>&#x02013;<lpage>1426</lpage>.</mixed-citation></ref><ref id="pone.0185449.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Post</surname><given-names>MS</given-names></name>, <name><surname>Verhoeven</surname><given-names>MO</given-names></name>, <name><surname>van der Mooren</surname><given-names>MJ</given-names></name>, <name><surname>Kenemans</surname><given-names>P</given-names></name>, <name><surname>Stehouwer</surname><given-names>CDA</given-names></name>, <name><surname>Teerlink</surname><given-names>T</given-names></name>. <article-title>Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>: <fpage>4221</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2003-030584">10.1210/jc.2003-030584</ext-link></comment>
<pub-id pub-id-type="pmid">12970290</pub-id></mixed-citation></ref><ref id="pone.0185449.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Yilmaz</surname><given-names>MI</given-names></name>, <name><surname>Saglam</surname><given-names>M</given-names></name>, <name><surname>Caglar</surname><given-names>K</given-names></name>, <name><surname>Cakir</surname><given-names>E</given-names></name>, <name><surname>Sonmez</surname><given-names>A</given-names></name>, <name><surname>Ozgurtas</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine</article-title>. <source>Am J Kidney Dis</source>. <year>2006</year>;<volume>47</volume>: <fpage>42</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.ajkd.2005.09.029">10.1053/j.ajkd.2005.09.029</ext-link></comment>
<pub-id pub-id-type="pmid">16377384</pub-id></mixed-citation></ref><ref id="pone.0185449.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Lundwall</surname><given-names>K</given-names></name>, <name><surname>J&#x000f6;rneskog</surname><given-names>G</given-names></name>, <name><surname>Jacobson</surname><given-names>SH</given-names></name>, <name><surname>Spaak</surname><given-names>J</given-names></name>. <article-title>Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial</article-title>. <source>Am J Nephrol</source>. <year>2015</year>;<volume>42</volume>: <fpage>265</fpage>&#x02013;<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000441364">10.1159/000441364</ext-link></comment>
<pub-id pub-id-type="pmid">26496210</pub-id></mixed-citation></ref><ref id="pone.0185449.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Ngo</surname><given-names>DT</given-names></name>, <name><surname>Sverdlov</surname><given-names>AL</given-names></name>, <name><surname>McNeil</surname><given-names>JJ</given-names></name>, <name><surname>Horowitz</surname><given-names>JD</given-names></name>. <article-title>Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?</article-title>
<source>Am J Med</source>. Elsevier Inc.; <year>2010</year>;<volume>123</volume>: <fpage>335</fpage>&#x02013;<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjmed.2009.09.024">10.1016/j.amjmed.2009.09.024</ext-link></comment>
<pub-id pub-id-type="pmid">20362753</pub-id></mixed-citation></ref><ref id="pone.0185449.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Burnett-Bowie</surname><given-names>S-AM</given-names></name>, <name><surname>Leder</surname><given-names>BZ</given-names></name>, <name><surname>Henao</surname><given-names>MP</given-names></name>, <name><surname>Baldwin</surname><given-names>CM</given-names></name>, <name><surname>Hayden</surname><given-names>DL</given-names></name>, <name><surname>Finkelstein</surname><given-names>JS</given-names></name>. <article-title>Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23</article-title>. <source>Clin J Am Soc Nephrol</source>. American Society of Nephrology; <year>2012</year>;<volume>7</volume>: <fpage>624</fpage>&#x02013;<lpage>631</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2215/CJN.10030911">10.2215/CJN.10030911</ext-link></comment>
<pub-id pub-id-type="pmid">22300739</pub-id></mixed-citation></ref><ref id="pone.0185449.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Tripepi</surname><given-names>G</given-names></name>, <name><surname>Jager</surname><given-names>KJ</given-names></name>, <name><surname>Dekker</surname><given-names>FW</given-names></name>, <name><surname>Zoccali</surname><given-names>C</given-names></name>. <article-title>Selection bias and information bias in clinical research</article-title>. <source>Nephron Clin Pract</source>. <year>2010</year>;<volume>115</volume>: <fpage>0</fpage>&#x02013;<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000312871">10.1159/000312871</ext-link></comment>
<pub-id pub-id-type="pmid">20407272</pub-id></mixed-citation></ref><ref id="pone.0185449.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Teng</surname><given-names>M</given-names></name>, <name><surname>Wolf</surname><given-names>M</given-names></name>, <name><surname>Lowrie</surname><given-names>E</given-names></name>, <name><surname>Ofsthun</surname><given-names>N</given-names></name>, <name><surname>Lazarus</surname><given-names>JM</given-names></name>, <name><surname>Thadhani</surname><given-names>R</given-names></name>. <article-title>Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>: <fpage>446</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa022536">10.1056/NEJMoa022536</ext-link></comment>
<pub-id pub-id-type="pmid">12890843</pub-id></mixed-citation></ref><ref id="pone.0185449.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>JE</given-names></name>, <name><surname>Molnar</surname><given-names>MZ</given-names></name>, <name><surname>Kovesdy</surname><given-names>CP</given-names></name>, <name><surname>Zaritsky</surname><given-names>JJ</given-names></name>, <name><surname>Streja</surname><given-names>E</given-names></name>, <name><surname>Salusky</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. NIH Public Access; <year>2012</year>;<volume>21</volume>: <fpage>1232</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/pds.3349">10.1002/pds.3349</ext-link></comment>
<pub-id pub-id-type="pmid">22996597</pub-id></mixed-citation></ref><ref id="pone.0185449.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Thadhani</surname><given-names>R</given-names></name>, <name><surname>Appelbaum</surname><given-names>E</given-names></name>, <name><surname>Pritchett</surname><given-names>Y</given-names></name>, <name><surname>Chang</surname><given-names>Y</given-names></name>, <name><surname>Wenger</surname><given-names>J</given-names></name>, <name><surname>Tamez</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>: <fpage>674</fpage>&#x02013;<lpage>684</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2012.120">10.1001/jama.2012.120</ext-link></comment>
<pub-id pub-id-type="pmid">22337679</pub-id></mixed-citation></ref></ref-list></back></article>